Table 2.
Angiographic, echocardiographic and biochemical characteristics of study population
| Variable | Overall study population (n = 204) | Patients with LVSD (n = 57) | Patients without LVSD (n = 147) | p for comparison between groups with and without LVSD |
|---|---|---|---|---|
| Angiographic indices | ||||
| IRA: LAD/non-LAD, n (%) | 93 (45.6)/111 (54.4) | 52 (91.2)/5 (8.8) | 41 (27.9)/106 (72.1) | <0.001 |
| Multivessel coronary artery disease, n (%) | 123 (60.3) | 38 (66.7) | 85 (57.8) | NS |
| Stenosis in IRA in QCA (%) | ||||
| Before pPCI | 93.9 ± 9.5 | 95.5 ± 9.2 | 93.3 ± 9.5 | 0.035 |
| After pPCI | 11.7 ± 10.1 | 10.6 ± 8.2 | 12.1 ± 10.7 | NS |
| TFC in IRA (frames/s) | ||||
| Before pPCI | 74.6 ± 33.5 | 83.1 ± 29.2 | 71.3 ± 34.6 | 0.021 |
| After pPCI | 25.8 ± 17.9 | 28.0 ± 15.2 | 24.9 ± 18.9 | 0.017 |
| TIMI 3 flow in IRA, n (%) | ||||
| Before pPCI | 58 (28.4) | 6 (10.5) | 52 (35.4) | <0.001 |
| After pPCI | 190 (93.1) | 50 (87.7) | 140 (95.3) | NS |
| TMPG 3 after pPCI, n (%) | 94 (46.1) | 28 (49.1) | 66 (44.9) | NS |
| Patients with implanted stents, n (%) | 202 (99.0) | 57 (100) | 145 (98.6) | NS |
| Patients with implanted DES, n (%) | 4 (2.0) | 2 (3.6) | 2 (1.4) | NS |
| Abciximab use, n (%) | 50 (24.5) | 23 (41.1) | 27 (18.6) | <0.001 |
| Echocardiographic indices | ||||
| LA (mm) | 39.7 ± 4.5 | 41.1 ± 5.3 | 39.1 ± 4.1 | 0.029 |
| LVEDd (mm) | 48.7 ± 5.5 | 51.4 ± 5.1 | 47.6 ± 5.3 | <0.001 |
| LVESd (mm) | 33.8 ± 4.8 | 36.8 ± 5.1 | 32.6 ± 4.2 | <0.001 |
| LVMI (g/m²) | 115.7 ± 25.2 | 136.1 ± 24.7 | 107.8 ± 20.5 | <0.001 |
| LVEDVI (mL/m2) | 53.0 ± 12.6 | 60.5 ± 14.5 | 50.1 ± 10.5 | <0.001 |
| LVESVI (mL/m2) | 29.7 ± 9.5 | 38.5 ± 10.5 | 26.3 ± 9.5 | <0.001 |
| WMSI (points) | 1.6 ± 0.2 | 1.8 ± 0.1 | 1.5 ± 0.2 | <0.001 |
| S′ (cm/s) | 7.2 ± 1.4 | 6.1 ± 1.1 | 7.6 ± 1.4 | <0.001 |
| S″ (cm/s) | 7.2 ± 1.5 | 6.1 ± 1.1 | 7.6 ± 1.4 | <0.001 |
| Biochemical parameters | ||||
| Creatinine (μmol/L) | 85.0 ± 15.7 | 87.6 ± 16.7 | 84.0 ± 15.2 | NS |
| Admission glucose (mmol/L) | 8.46 ± 3.05 | 9.77 ± 4.24 | 7.96 ± 2.26 | 0.002 |
| HbA1c (%) | 6.3 ± 1.1 | 6.6 ± 1.4 | 6.2 ± 1.0 | NS |
| TnImax (ng/mL) | 32.1 ± 19.6 | 43.4 ± 14.3 | 27.7 ± 19.7 | <0.001 |
| CK-MBmax (U/L) | 120.5 ± 81.6 | 158.1 ± 86.3 | 105.5 ± 74.8 | <0.001 |
| Leukocyte count at admission (103 per μL) | 11.2 ± 3.0 | 11.6 ± 2.8 | 11.1 ± 3.0 | NS |
| Leukocyte count 24 h after admission (103 per μL) | 10.3 ± 2.6 | 11.5 ± 3.0 | 9.9 ± 2.2 | <0.001 |
| BNP at admission (pg/mL) | 87.1 ± 140.0 | 136.8 ± 230.4 | 67.9 ± 74.6 | 0.002 |
| BNP at discharge (pg/mL) | 205.0 ± 260.2 | 401.0 ± 386.0 | 129.0 ± 127.0 | <0.001 |
Echocardiographic indices are derived from 2D and Doppler echocardiography and tissue Doppler echocardiography at hospital discharge
BNP B-type natriuretic peptide, CK-MB max maximal activity of isoenzyme MB of creatine kinase, DES drug-eluting stent, IRA infarct-related artery, LA left atrium; LAD left anterior descending artery, LVEDd left ventricular end-diastolic diameter, LVEDVI left ventricular end-diastolic volume index, LVESd left ventricular end-systolic diameter, LVESVI left ventricular end-systolic volume index; LVMI left ventricle mass index, LVSD left ventricular systolic dysfunction, pPCI primary percutaneous coronary intervention, TnI max maximal concentration of troponin I, TIMI Thrombolysis in Myocardial Infarction score, TFC TIMI frame count, TMPG TIMI Myocardial Perfusion Grade, S′ average peak systolic mitral annular velocity, S″ average septal and lateral peak systolic mitral annulus velocity, WMSI wall motion score index